| Michelle Owens, DPT, ATC | |
|
6069 S Highland Dr, Holladay, UT 84121-1375 | |
| (801) 944-1209 | |
| Not Available |
| Full Name | Michelle Owens |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | 6069 S Highland Dr, Holladay, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780093146 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 9057855-2401 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michelle Owens, DPT, ATC 6069 S Highland Dr, Holladay, UT 84121-1375 Ph: (801) 944-1209 | Michelle Owens, DPT, ATC 6069 S Highland Dr, Holladay, UT 84121-1375 Ph: (801) 944-1209 |
News Archive
A comprehensive, population-based strategy is needed to reduce the alarming prevalence of obesity in the United States, according to a new American Heart Association scientific statement published in Circulation: Journal of the American Heart Association.
Vitamin D can inhibit the spread of prostate cancer cells by limiting the activity of two specific enzymes, University of Rochester Medical Center scientists report.
On Monday 4 February, Dennis J. Selkoe and five other "brain teasers" will receive an honorary doctorate from the KU Leuven. The promoters for this honorary doctorate - VIB-KU Leuven professors Bart De Strooper and Wim Robberecht - will honor Dennis J. Selkoe for his scientific insights, but also for his relentless search for new medicines to treat Alzheimer's Disease and other conditions that cause severe damage in the brain.
Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.
Research from Western University (London, Canada) has revealed a possible new target for treating movement disorders such as Huntington's disease (HD) and Parkinson's disease. Stephen Ferguson, PhD, a scientist at Western's Robarts Research Institute, and Fabiola Ribeiro, PhD, of the Universidade Federal de Minas Gerais in Brazil found a definite improvement in motor behaviors in a HD mouse model when one of the major neurotransmitters in the brain, called Metabotropic Glutamate Receptor 5 (mGluR5) was deleted.
› Verified 8 days ago
Canyon Sports Therapy Inc Physical Therapist Medicare: Medicare Enrolled Practice Location: 6069 Highland Dr, Holladay, UT 84121 Phone: 801-944-1209 Fax: 801-274-1180 | |
Nathan Paul Philpott, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4600 Wellington St, Holladay, UT 84117 Phone: 801-815-2045 | |
Steady And Well Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4600 S Wellington St, Holladay, UT 84117 Phone: 801-815-2045 | |
Jeremy Christopher Mccorristin, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4782 S Holladay Blvd, Holladay, UT 84117 Phone: 801-277-7002 | |
Melissa Jayne Allen, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4624 S Holladay Blvd Ste 2, Holladay, UT 84117 Phone: 801-277-1028 | |
Mvp Sports Science Institute Inc Physical Therapist Medicare: Medicare Enrolled Practice Location: 1826 Cottonwood Club Dr, Holladay, UT 84117 Phone: 801-244-1292 Fax: 801-273-7474 | |
Mr. Stanley Ardel Bingham, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2040 Murray Holladay Rd, 205, Holladay, UT 84117 Phone: 801-274-0299 Fax: 801-274-0947 |